An Italian research team's findings support claims made by
Dunedin biotech company Blis Technologies regarding the
effectiveness of its probiotic product in preventing ear and
throat infections in adults.
The medical science journal Expert Opinion on Biological
Therapy has published the findings of an Italian research
team, which monitored 40 adults with a history of recurrent
ear and throat infection who used Blis K129, or a placebo,
for 90 days.
The research team demonstrated the product could prevent the
recurrence of common ear and throat infections, such as strep
throat and tonsillitis, by more than 83% in adults, Blis'
chief executive, Dr Barry Richardson, said in a statement to
the stock exchange last week.
''It is reassuring to us to know that Blis K129 has been
independently supported as being highly efficacious in both
children and adults,'' Dr Richardson said.
The Italian findings come two months after a similar research
paper found regular use of the Blis K12 product by children
could reduce the incidence of strep throat infection,
including tonsillitis, by more than 92%.